GlaxoSmithKline has acquired Okairos AG (Okairos), a specialist developer of vaccine platform technologies for €250 million (approximately £215 million/$325 million) in cash. The deal gives GSK...

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]